Compare · SYK vs XAIR
SYK vs XAIR
Side-by-side comparison of Stryker Corporation (SYK) and Beyond Air Inc. (XAIR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYK and XAIR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 53145.4x XAIR ($2.1M).
- Over the past year, SYK is down 21.3% and XAIR is down 95.2% - SYK leads by 73.9 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 6 for XAIR).
- SYK has more recent analyst coverage (25 ratings vs 6 for XAIR).
- Company
- Stryker Corporation
- Beyond Air Inc.
- Price
- $294.69+0.46%
- $2.24+7.18%
- Market cap
- $112.48B
- $2.1M
- 1M return
- +5.16%
- -27.74%
- 1Y return
- -21.34%
- -95.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 6
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Beyond Air Inc.
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)
Latest XAIR
- SEC Form 4 filed by Beyond Air Inc.
- SEC Form 8-K filed by Beyond Air Inc.
- Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
- Large owner Lin Yi-Chien bought $56,590 worth of shares (20,393 units at $2.77), increasing direct ownership by 16% to 145,393 units (SEC Form 4)
- New insider Lin Yi-Chien claimed ownership of 125,000 shares (SEC Form 3)
- Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update
- Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
- Lake Street initiated coverage on Beyond Air with a new price target
- Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
- Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments